News

  • 2 May 2017

    Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and fecal dysfunction, announced today that it has completed a $14.5 million first closing of its Series C financing.

  • 26 April 2017

    Company set to advance pipeline of monoclonal antibodies for serious infectious diseases, including lead Phase 2 program ASN100 for the prevention of Staphylococcus aureus pneumonia in high-risk ICU patients.

  • 24 April 2017

    Wilson Therapeutics AB (publ), announced today that the final data from the company’s Phase 2 trial of WTX101 (bis-choline tetrathiomolybdate), an investigational first-in-class copper modulating agent with a unique mode of action for the treatment of patients with Wilson Disease, were presented as a late breaker presentation at The International Liver Congress™ 2017. The congress is the Annual Meeting of the European Association for the Study of the Liver (EASL), held in Amsterdam, the Netherlands, 19 – 23 April. The data were presented by Prof. Karl Heinz Weiss, MD, University of Heidelberg. The presentation included the final results of all hepatic parameters studied in the Phase 2 study of WTX101, as well as copper control and neurological outcomes over the course of the study. As previously reported, the Phase 2 study of WTX101 met its primary endpoint of copper control (p< 0.001). 

  • 24 April 2017

    Sienna Biopharmaceuticals, Inc., a privately held, clinical stage medical dermatology and aesthetics company, today announced that it completed a $40 million Series B financing led by existing investors ARCH Venture Partners and Venvest Capital. Additional investors participating included Partner Fund Management, Altitude Life Science Ventures, and Dr. David Pyott.  New investors accounted for approximately half of the investments and included Fidelity Management & Research Company, certain investment funds advised by Clough Capital Partners L.P, Omega Fund Management, and others.  Sienna’s mission is to develop safe and effective targeted therapies to treat inflammatory skin conditions and aesthetic problems that impact the health, appearance, and quality of life of patients.

  • 18 April 2017

    Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and fecal dysfunction, announced today that initial results from its prospective, multicenter clinical study will be presented for the first time at the International Neuromodulation Society (INS) World Congress on May 30, 2017 in Edinburgh, Scotland.